baito logo
    navigation?.buttons?.createJob?.text
    Mindpeak header
    Mindpeak logo
    #krebsdiagnostik #künstlicheintelligenz #digitalepathologie

    Mindpeak

    from Hamburg

    Mindpeak GmbH revolutionizes cancer diagnostics through AI-supported digital pathology solutions. With innovative algorithms like "BreastIHC," the company supports pathologists worldwide to enable faster and more accurate diagnoses. Committed to better treatment outcomes and sustainable innovation.

    Visit website

    Mindpeak: Revolutionizing Cancer Diagnostics through Artificial Intelligence

    About Mindpeak

    Mindpeak, founded in 2018 in Hamburg, Germany, is a global innovator in the field of AI-powered digital pathology solutions. The company was established by Felix Faber and Dr. Tobias Lang with the goal of revolutionizing cancer diagnostics through the use of Artificial Intelligence.

    Key Products and Services

    Mindpeak develops and implements state-of-the-art AI algorithms that assist pathologists in routine diagnostics. One of the main solutions is the deep learning application "BreastIHC," which is used for the detection, classification, and quantification of breast cancer cells. This technology enables automated histological and immunohistochemical tissue analysis, leading to faster and more accurate diagnostic results. Mindpeak's algorithms have already been approved for clinical routine diagnostics in the USA and the EU and are used in over ten laboratories worldwide[2][4].

    Mission and Values

    The main mission of Mindpeak is to make cancer diagnostics using Artificial Intelligence quickly and cost-effectively available to all people. The company aims to improve treatment outcomes for cancer patients by providing pathologists and researchers with innovative and reliable diagnostic tools. Mindpeak focuses on collaboration between humans and machines to optimize medical diagnostics and allow doctors more time for patient care[2][3].

    Sustainability Goals and Initiatives

    Mindpeak is strongly committed to promoting innovations in digital pathology. The company has established strategic partnerships with leading health organizations such as Roche and benefits from regulatory support and funding programs, including the EU's EIC Accelerator funding and grants from IFB Hamburg. This support enables Mindpeak to further develop and expand its technologies globally to respond to the increasing number of cancer cases[1][2].

    Current Developments

    Mindpeak recently raised $15.3 million in a Series A funding round led by ZEISS Ventures and InnoVentureFund. This investment will be used to accelerate the commercialization of groundbreaking technologies in several regions and to further advance product development. To date, Mindpeak's AI solutions have supported over 30,000 patient diagnoses and are also used in the biopharmaceutical industry to predict the effectiveness of drugs in cancer therapy[1].

    Sources: